| Metric | Q3 FY26 | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Other income | 0.1 | 0.0 | 0.1 |
| Total income | 1.0 | 2.0 | 2.7 |
| Net profit | -0.5 | -0.3 | -0.4 |
| Operating margin | -50.0% | -15.0% | -14.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
BSE results filing, NSE: KAPILCO. Figures extracted from the filing.
Skybiotech Healthcare Ltd: key numbers
- Share price
- ₹116.20
- Market cap
- ₹22.25 Cr
- Revenue (annual)
- ₹7.10 Cr
- Net profit (annual)
- ₹-1.12 Cr
- P/E (TTM)
- -13.3×Sector 53.6×
- Promoter holding
- 63.48%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Skybiotech Healthcare Ltd
All →Skybiotech Healthcare Annual General Meeting
Skybiotech Healthcare Ltd has issued the notice for its 43rd Annual General Meeting. The meeting is scheduled to be held on September 30, 2026.
Skybiotech Healthcare Annual Report
Skybiotech Healthcare Ltd has filed its Annual Report for the financial year 2025-26, pursuant to Regulation 34 of the SEBI LODR Regulations.
Skybiotech Healthcare Q1 FY27 Results: Net Loss of ₹0.6 Cr
Skybiotech Healthcare Ltd reported revenue from operations of ₹0.5 Cr (-79.2% YoY) and a net loss of ₹0.6 Cr for Q1 FY27.
- Key figure
- Net loss ₹0.6 Cr
Skybiotech Healthcare Board Meeting Date
Skybiotech Healthcare Limited has scheduled a board meeting for August 14, 2026. The board will consider and approve un-audited financial results for the quarter ended June 30, 2026.
Skybiotech Healthcare Other Announcement
Skybiotech Healthcare Ltd filed its quarterly shareholding pattern for the period ended June 30, 2026, as required by SEBI regulations.
Skybiotech Healthcare Other Announcement
Skybiotech Healthcare Ltd has filed its quarterly shareholding pattern statement as per regulatory requirements. This document details the company's equity distribution across various shareholder categories.